Penserra Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Penserra Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-41,296	Closed	-$4.08M	–	1207
2024 Q3	$4.08M	Sell	41,296 -1,521	-4%	-$149K	0.09%	213
2024 Q2	$3.97M	Buy	+42,817	New	+$3.84M	0.05%	263
2020 Q3	–	Sell	-3,616	Closed	-$404K	–	1047
2020 Q2	$404K	Buy	+3,616	New	+$356K	0.02%	388
2018 Q2	–	Sell	-18,109	Closed	-$1.59M	–	613
2018 Q1	$1.59M	Buy	+18,109	New	+$1.65M	0.15%	106

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Penserra Capital Management's XBI Position: Q4 2024 in Review

Penserra Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 41,296 shares — an estimated $4.08M sold.

Penserra Capital Management first reported a position in XBI in Q1 2018 and held it in 4 quarters. The position peaked at $4.08M in Q3 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Penserra Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Penserra Capital Management sold 41,296 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $4.08M.
Penserra Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and held it in 4 quarters.
Penserra Capital Management's State Street SPDR S&P Biotech ETF position peaked at $4.08M in Q3 2024.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Penserra Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.